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Introduction {#sec005}
============

Coronary heart disease (CHD) is a type of cardiovascular disease that is caused by ischemia and hypoxia in the coronary artery \[[@pone.0135683.ref001]\] and is the leading cause of human deaths worldwide \[[@pone.0135683.ref002]--[@pone.0135683.ref004]\]. CHD is the most common cause of death among both men and women over the age of 50 \[[@pone.0135683.ref005]\]. Environmental factors associated with CHD include obesity, smoking, drinking, diabetes, arterial hypertension and dyslipidemia \[[@pone.0135683.ref006]\]. In addition, genetic factors are important for CHD \[[@pone.0135683.ref007]\].

*APOA5* is located in the apolipoprotein APOA1/C3/A4 gene cluster \[[@pone.0135683.ref008]\] on chromosome 11q23 \[[@pone.0135683.ref008],[@pone.0135683.ref009]\]. *APOA5* is predominantly expressed in hepatocytes and secreted into the blood \[[@pone.0135683.ref010],[@pone.0135683.ref011]\]. The APOA5 apolipoprotein plays a key role in the synthesis and removal of triglycerides (TG) \[[@pone.0135683.ref005]\]. Increased levels of apolipoprotein A5 are correlated with decreased TG levels in the serum \[[@pone.0135683.ref005]\].

Atherogenic dyslipidemia is a major risk factor for CHD \[[@pone.0135683.ref012]--[@pone.0135683.ref014]\], as are blood lipid levels \[[@pone.0135683.ref006]\]. Blood lipids mainly consist of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and TG \[[@pone.0135683.ref012]\]. In addition to LDL-C and HDL-C levels, *APOA5* is associated with TG levels \[[@pone.0135683.ref013]\]. *APOA5* plays an important role in determining TG levels in serum \[[@pone.0135683.ref014]\]. TG interacts with lipoprotein lipase, an enzyme important for the central regulation of circulating TG levels \[[@pone.0135683.ref015]\]. In mice, over expression of *Apoa5* leads to decreased concentrations of TG in plasma, whereas a shortage of apoA5 causes hypertriglyceridemia, a risk factor for atherosclerosis and CHD \[[@pone.0135683.ref016]\]. These findings are consistent with observations in humans \[[@pone.0135683.ref017]\]. Taken together, these studies indicate that *APOA5* is associated with CHD \[[@pone.0135683.ref018]--[@pone.0135683.ref020]\].

*APOA5* rs662799 (-1131T\>C) is a promoter polymorphism that was shown to be associated with increased levels of TG in young adult Indians \[[@pone.0135683.ref021]\]. In Italians, *APOA5* is associated with TG leaves and acute myocardial infarction (MI) \[[@pone.0135683.ref013]\]. The significant association of rs662799 with TG and CHD was validated in a Japanese population \[[@pone.0135683.ref022]\]. According to the HapMap database, there are ethnic differences in *APOA5* rs662799 (A\>G). The minor allele frequency in European populations (HapMap-CEU) is 1.7%, much lower than the 13.3% observed in individuals of African descent (HapMap-YRI), 26.7% in Chinese (HapMap-CHB) and 28.9% in Japanese (HapMap-JPT). In our previous study, we could not detect a significant association between *APOA5* rs662799 and CHD \[[@pone.0135683.ref023]\], possibly due to a lack of power. Here, we increased the sample size to determine whether *APOA5* rs662799 plays a role in the risk of CHD in Han Chinese.

Materials and Methods {#sec006}
=====================

Sample collection {#sec007}
-----------------

Samples from 1,521 unrelated individual inpatients were randomly collected from the Ningbo Lihuili Hospital and the Ningbo Yinzhou People\'s Hospital, Zhejiang, China. The samples included 783 cases of CHD (537 males and 246 females) and 738 controls (421 males and 317 females). All individuals were free from congenital heart disease, cardiomyopathy and severe liver or kidney disease. Details of the classified criteria have been described in our previous studies \[[@pone.0135683.ref002],[@pone.0135683.ref024]--[@pone.0135683.ref027]\]. The study protocol was approved by the Ethical Committees of Ningbo Lihuili Hospital and Ningbo Yinzhou People\'s Hospital, and informed written consent was obtained from all subjects. The clinical and demographic details of CHD samples are summarized in [S1 Table](#pone.0135683.s003){ref-type="supplementary-material"}.

SNP Genotyping {#sec008}
--------------

Genomic DNA was isolated from peripheral blood lymphocytes using a nucleic acid extraction automatic analyzer (Lab-Aid 820, Xiamen, China). PCR was performed on the ABI GeneAmp PCR System 9700 Dual 384-Well Sample Block Module (Applied Biosystems, Foster City, CA, USA). PCR conditions included an initial denaturation of 95°C for 2 min, followed by 45 cycles of 95°C for 30 sec, 56°C for 30 s, 72°C for 1 min and then a final extension at 72°C for 5 min. After purification by SAP Reaction, we proceeded with primer extension. The primer extension protocol included an initial denaturation at 94°C for 30 s, followed by 40 cycles of amplification (including 94°C for 5 s, 52°C for 5 s, 80°C for 5 s), 5 cycles of amplification (5 s at 52°C, 5 s at 80°C), a final extension at 72°C for 3 min after which samples were held at 4°C. Single nucleotide polymorphism genotyping was performed using the Sequenom Mass-ARRAY iPLEX platform per the manufacturer\'s instructions \[[@pone.0135683.ref028]\]. The primer sequences were 5'- ACGTTGGATGAGCATTTGGGCTTGCTCTCC-3' (first primer), 5'-ACGTTGGATGTCTGAGCCCCAGGAACTGGA-3' (second primer) and 5'- caGAACTGGAGCGAAAGT-3' (extended primer).

Publication retrieval and data extraction {#sec009}
-----------------------------------------

The literatures were searched in the online databases including PubMed and Wanfang between Jan 2000 and Jul 2015. The keywords were "coronary heart disease", "coronary artery disease" or "myocardial infarction" combined with "APOA5" and "rs662799" or "-1131T\>C". All of the case-control studies between APOA5 rs662799 and CHD were retrieved for the consideration of the current meta-analysis. All of the case-control studies between *APOA5* (rs662799) and CHD were considered to be eligible for the current meta-analysis. We only included studies that presented data on allele or genotype frequencies for both cases and controls and displayed a genotype distribution meeting Hardy-Weinberg equilibrium (HWE) \[[@pone.0135683.ref029]\]. Information in the meta-analysis included the first author's name, publication year, country, ethnic group, number of alleles or genotypes and the total number of cases and controls. The details on the inclusion criteria included as follow:1) only the case-control studies on the association between rs662799 and CHD were included; 2) the eligible studies must contain the odds ratios (ORs) and 95% confidence intervals (CIs), or the genotype or allele information to calculate ORs and 95% Cis; 3) HWE should be met for the genotype distribution in the control group of the eligible studies if they have genotype information. We directly emailed the corresponding authors or called them (only for authors in China) for the missing information in their studies. There were 214 studies retrieved from the Wanfang and CNKI literature databases after searching for the keywords "coronary heart disease", "coronary artery disease" or "myocardial infarction" combined with "*APOA5*" and "rs662799" or "-1131T\>C". After a series of selection procedures, we excluded 15 duplicate studies, 5 meta-analysis studies, 120 irrelevant studies, 28 studies on other diseases, and 7 studies without genotyping data ([S1 File](#pone.0135683.s002){ref-type="supplementary-material"}). In addition, we further downloaded the GWAS dataset from WTCCC research, then we imputed the information of rs662799 genotype by MaCH-Admix in WTCCC database, and added the data to the meta-analysis \[[@pone.0135683.ref030]\]. The remaining 40 case-control studies were qualified for our meta-analysis ([Fig 1](#pone.0135683.g001){ref-type="fig"}) \[[@pone.0135683.ref011],[@pone.0135683.ref013],[@pone.0135683.ref017],[@pone.0135683.ref020],[@pone.0135683.ref022],[@pone.0135683.ref031]--[@pone.0135683.ref063]\].

![Flow chart of the meta-analysis.](pone.0135683.g001){#pone.0135683.g001}

Statistical analyses {#sec010}
--------------------

The HWE test was performed using the Arlequin program (version 3.5), and P \> 0.05 was considered to be in HWE \[[@pone.0135683.ref064]\]. Genotype and allele distribution was compared between cases and controls by CLUMP22 software using 10,000 Monte Carlo simulations \[[@pone.0135683.ref065]\]. The odds ratio (OR) with a 95% confidence interval (CI) were determined using an online program, (<http://faculty.vassar.edu/lowry/odds2x2.html>) \[[@pone.0135683.ref023]\]. Meta-analysis was performed using the Review Manager software set to the fixed-effect or random-effect method (version 5.0, Cochrane Collaboration, Oxford, United Kingdom) \[[@pone.0135683.ref066]\]. Heterogeneity in the meta-analysis was assessed using the Q and I^2^ tests. An I^2^ \> 50% indicated the existence of heterogeneity among the studies in the meta-analysis. Publication bias was shown by Begg's funnel plot analysis, which was generated with Stata software (version 11.0, Stata Corporation, College Station, TX, USA). P values \< 0.05 were significant.

Results {#sec011}
=======

No departure from HWE was observed for the *APOA5* rs662799 polymorphism in cases (P = 0.220) or controls (P = 0.544). Genotypic and allelic comparisons between cases and controls are shown in [Table 1](#pone.0135683.t001){ref-type="table"}. Our data show that rs622799 is associated with the risk of CHD (genotype: χ^2^ = 8.964, df = 2, P = 0.011; allele: P = 0.002; OR = 1.275, 95% CI = 1.089--1.492). A further gender-stratified association shows that rs662799 is significantly associated with CHD in males ([Table 1](#pone.0135683.t001){ref-type="table"}, genotype: χ^2^ = 7.486, df = 2, P = 0.024; allele: χ^2^ = 7.770, df = 1, P = 0.005) but not in females. In addition, frequency of the rs662799-G allele is significantly higher in male cases (31.5%) than in male controls (25.7%, P = 0.005; OR = 1.331, 95% CI = 1.088--1.628; [Table 1](#pone.0135683.t001){ref-type="table"}). A further breakdown analysis by age shows that the frequency of rs662799-G is significantly higher in CHD cases with ages ranging from 55 to 65 years (31.5% versus 25.0%, χ^2^ = 5.700, df = 1, P = 0.017, OR = 1.383, 95% CI = 1.059--1.805; [Table 2](#pone.0135683.t002){ref-type="table"}).

10.1371/journal.pone.0135683.t001

###### Genotype and allele frequencies in cases and controls.

![](pone.0135683.t001){#pone.0135683.t001g}

                                         Genotype \[n, (%)\]   χ^2^         P (df = 2)   HWE     Allele (counts)   χ^2^    P (df = 1)   OR (95% CI)                                  
  -------------------- ----------------- --------------------- ------------ ------------ ------- ----------------- ------- ------------ ------------- ------- ---------------------- --
  All                  Cases (N = 783)   85(10.9%)             323(41.3%)   375(47.8%)                             0.220   493          1,073                                        
  Controls (N = 738)   55(7.5%)          281(38.1%)            402(54.4%)   8.964        0.011   0.544             391     1,085        9.180         0.002   1.275 (1.089--1.492)   
  Male                 Cases (N = 537)   58(10.8%)             222(41.3%)   257(47.9%)                             0.335   338          736                                          
  Controls (N = 421)   32(7.6%)          152(36.1%)            237(56.3%)   7.486        0.024   0.272             216     626          7.770         0.005   1.331 (1.088--1.628)   
  Female               Cases (N = 246)   27(11.0%)             101(41.1%)   118(47.9%)                             0.445   155          337                                          
  Controls (N = 317)   23(7.3%)          129(40.7%)            165(52.0%)   2.622        0.270   0.746             175     459          2.040         0.153   1.206 (0.932--1.561)   

10.1371/journal.pone.0135683.t002

###### Genotype and allele frequencies in cases and controls with different age ranges.

![](pone.0135683.t002){#pone.0135683.t002g}

                                         Genotype \[n, (%)\]   χ^2^         P (df = 2)   HWE     Allele (counts)   χ^2^    P (df = 1)   OR (95% CI)                                  
  -------------------- ----------------- --------------------- ------------ ------------ ------- ----------------- ------- ------------ ------------- ------- ---------------------- --
  55≤                  Cases (N = 179)   20(11.2%)             68(38.0%)    91(50.8%)                              0.188   108          250                                          
  Controls (N = 239)   18(7.5%)          93(38.9%)             128(53.6%)   1.660        0.436   0.846             129     349          1.02          0.313   1.169 (0.863--1.582)   
  55--65               Cases (N = 271)   27(10.0%)             117(43.2%)   127(46.8%)                             0.994   171          371                                          
  Controls (N = 268)   17(6.3%)          100(37.3%)            151(56.4%)   5.660        0.059   0.935             134     402          5.700         0.017   1.383 (1.059--1.805)   
  ≥65                  Cases (N = 333)   38(11.4%)             138(41.4%)   157(47.2%)                             0.363   214          452                                          
  Controls (N = 231)   20(8.7%)          88(38.1%)             123(53.2%)   2.409        0.300   0.456             128     334          2.530         0.112   1.235 (0.952--1.603)   

Meta-analysis {#sec012}
-------------

Searching the existing literature databases, we found 40 case-control studies, 30 more cases than were used in the most recently published meta-analysis in 2013 \[[@pone.0135683.ref023]\]. Therefore, we performed an updated meta-analysis to investigate the link between rs662799 and CHD. Information from these 40 eligible studies and our case-control study are shown in [Table 3](#pone.0135683.t003){ref-type="table"}. Among the 40 eligible studies in the current meta-analysis, 7 studies only had allelic information. Therefore, allele-based model was applied in the meta-analysis. For the meta-analysis with moderate heterogeneity (I^2^ \< 50%), we selected a fixed-effect model for the meta-analysis, otherwise, the random-effect model was used for the meta-analysis with great heterogeneity (I^2^ \> = 50%). The current meta-analysis has great heterogeneity (I^2^ = 70%), therefore random-effect model was used. As shown in [Fig 2](#pone.0135683.g002){ref-type="fig"}, subgroup meta-analysis by major ethnic groups also indicates a significant association between *APOA5* rs662799 and CHD in Asians (P = 0.01, I^2^ = 66%), Chinese (P \< 0.000001, I^2^ = 67%) and Caucasians (P = 0.008, I^2^ = 60%). The meta-analyses show no publication bias by Begg's funnel plot analysis ([Fig 3](#pone.0135683.g003){ref-type="fig"}). Furthermore, sensitivity analysis suggests that the conclusion is not biased by any individual study ([Fig 4](#pone.0135683.g004){ref-type="fig"}).

![Forest plots of APOA5 rs662799 polymorphism with CHD risk in the Chinese, the Caucasian and the Asian populations\*.\
\*Events, the number of G alleles; total, total number of A and G alleles; our study: the CHD cases and controls in our study.](pone.0135683.g002){#pone.0135683.g002}

![Begg's funnel plot for the association between APOA5 rs662799 and CHD\*.\
\*Horizontal axis represents the standard error of log rr. Vertical axis represents the log rr. The s.e. denotes standard error.](pone.0135683.g003){#pone.0135683.g003}

![Sensitivity analysis for the APOA5 rs662799 polymorphism with CHD.](pone.0135683.g004){#pone.0135683.g004}

10.1371/journal.pone.0135683.t003

###### Detailed information of the *APOA5* rs662799 cases included in the meta-analysis.

![](pone.0135683.t003){#pone.0135683.t003g}

  Year   Author                                            Ethnic Group   NO. case/controls   NO. A allele   NO. G allele
  ------ ------------------------------------------------- -------------- ------------------- -------------- --------------
  2004   Bi N \[[@pone.0135683.ref040]\]                   Chinese        312/317             375/423        249/211
  2004   Hubacek JA \[[@pone.0135683.ref041]\]             Caucasian      435/2,559           778/4,683      92/435
  2004   Szalai C \[[@pone.0135683.ref042]\]               Hungarian      308/310             549/585        67/35
  2004   Wang CT \[[@pone.0135683.ref033]\]                Chinese        286/395             405/614        167/176
  2005   Liu HK \[[@pone.0135683.ref043]\]                 Chinese        483/502             588/704        378/300
  2005   Hsu LA \[[@pone.0135683.ref044]\]                 Chinese        211/317             291/446        131/188
  2005   Tang YB \[[@pone.0135683.ref045]\]                Chinese        235/262             280/344        190/180
  2005   Yan SK \[[@pone.0135683.ref046]\]                 Chinese        113/155             142/224        84/86
  2005   Ruiz-Narvoez EA \[[@pone.0135683.ref047]\]        Costa Rican    1,703/1,703         3,353/3,352    53/54
  2006   Havasi V \[[@pone.0135683.ref048]\]               Hungarian      302/289             534/550        70/28
  2006   Vaessen FC \[[@pone.0135683.ref049]\]             British        898/1,745           1,672/3,295    124/195
  2007   Qiu F \[[@pone.0135683.ref057]\]                  Chinese        260/316             358/477        162/155
  2007   Yang F \[[@pone.0135683.ref031]\]                 Chinese        168/160             196/221        140/99
  2007   Zhang YQ \[[@pone.0135683.ref058]\]               Chinese        141/129             167/174        115/84
  2007   Zhu MA \[[@pone.0135683.ref039]\]                 Chinese        119/210             141/284        97/136
  2007   Cheng XQ \[[@pone.0135683.ref037]\]               Chinese        112/113             138/162        136/86
  2007   Yu Y \[[@pone.0135683.ref050]\]                   Chinese        140/156             159/209        121/103
  2007   Li XP\[[@pone.0135683.ref038]\]                   Chinese        186/268             215/364        157/172
  2007   Martineli N \[[@pone.0135683.ref051]\]            Italian        669/244             1,208/445      130/43
  2007   Song DL \[[@pone.0135683.ref029]\]                Chinese        195/181             245/241        145/121
  2007   WTCCC \[[@pone.0135683.ref030]\]                  Caucasian      1926/2938           3604/5540      248/336
  2008   Xu L \[[@pone.0135683.ref059]\]                   Chinese        195/181             245/241        145/121
  2008   Zhao L \[[@pone.0135683.ref060]\]                 Chinese        155/145             178/193        132/97
  2008   Maasz A \[[@pone.0135683.ref052]\]                Hungarian      378/131             676/249        80/13
  2009   Zhang CJ \[[@pone.0135683.ref035]\]               Chinese        266/137             371/226        161/46
  2009   Jang Y \[[@pone.0135683.ref017]\]                 Korean         741/741             983/1,059      499/423
  2010   Ashokkumar M \[[@pone.0135683.ref053]\]           Indian         416/416             565/633        267/199
  2010   Provhaska CL \[[@pone.0135683.ref054]\]           Brazilian      180/170             327/316        33/24
  2010   Park JY \[[@pone.0135683.ref011]\]                Korean         807/1,123           1,093/1,587    521/659
  2010   Bhanushali AA \[[@pone.0135683.ref055]\]          Indian         90/150              58/120         32/30
  2011   Chen Y \[[@pone.0135683.ref061]\]                 Chinese        249/176             313/204        185/148
  2011   Han TL \[[@pone.0135683.ref032]\]                 Chinese        275/289             368/364        182/214
  2011   Raffaele De Caterina \[[@pone.0135683.ref013]\]   Italian        1,864/1,864         3,319/3,423    365/313
  2011   Bhaskar S \[[@pone.0135683.ref056]\]              Indian         250/120             355/181        145/59
  2012   Takeuchi F \[[@pone.0135683.ref022]\]             Japanese       4,399/7,672         5,701/10,250   3,097/5,094
  2012   Yan D \[[@pone.0135683.ref020]\]                  Chinese        229/254             269/350        189/158
  2012   He J \[[@pone.0135683.ref030]\]                   Chinese        54/58               83/91          25/25
  2012   Zhang XL \[[@pone.0135683.ref036]\]               Chinese        675/636             803/831        547/441
  2013   Dai HY \[[@pone.0135683.ref034]\]                 Chinese        158/130             244/138        72/122
  2014   Our study                                         Chinese        783/738             1,073/1,085    493/391

Discussion {#sec013}
==========

Our results show that the rs662799 polymorphism in the *APOA5* gene is significantly associated with CHD in Han Chinese (P = 0.011). The minor G allele of *APOA5* rs662799 may increase the risk of CHD by 27.5% (P = 0.002, OR = 1.275, 95% CI = 1.089--1.492). Consistent with previous reports, the rs662799-G allele is associated with higher leaves of TG in both CHD patients and controls \[[@pone.0135683.ref013],[@pone.0135683.ref067]\]. A power calculation for *APOA5* rs662799 indicates that our study has 85.9% power to detect significance in the association test.

Environmental factors, such as gender and age, are important factors of CHD. The prevalence of CHD in females was different from males \[[@pone.0135683.ref002],[@pone.0135683.ref068],[@pone.0135683.ref069]\]. Evidence has shown that patients older than 65 years have a higher cardiovascular morbidity and mortality \[[@pone.0135683.ref070],[@pone.0135683.ref071]\]. In the current meta-analysis, we were unable to perform the subgroup meta-analysis by the age or gender due to a paucity of related information in the involved studies.

Gender and age are independence risk of CHD \[[@pone.0135683.ref004],[@pone.0135683.ref072]--[@pone.0135683.ref074]\]. Epidemiologic evidence suggests that the risk of morbidity and mortality are higher in male CHD patients than in females \[[@pone.0135683.ref075]\]. Our data show a strong association between *APOA5* rs662799 and CHD in the male group, providing a novel molecular explanation for the gender disparity observed in CHD. In addition, we showed a statistically significant difference between rs662799 and CHD in the subgroup aged from 55--65, although the underlying mechanism will require additional studies.

The frequency of the *APOA5* rs662799 polymorphism varies greatly among different populations. The rs662799-G allele frequency is 26.7% in Chinese populations, similar to that in Japanese populations (29.1%). However, the Chinese frequency is much higher than that in European populations (1.7%). Nevertheless, accumulating evidence indicates a strong association between *APOA5* rs662799 and CHD among different populations. In addition to *APOA5* rs662799, there are associations between other *APOA5/A4/C3/A1* polymorphisms and CHD, which include *APOA5* rs3135506 and *APOA/A4/C3/A1* cluster haplotypes \[[@pone.0135683.ref076]\]. Further functional analysis is needed to discriminate the relationship among these polymorphisms.

There were other seven *APOA5* polymorphisms involved in the genetic studies ([S2 Table](#pone.0135683.s004){ref-type="supplementary-material"}). However, rs3135506 (n = 7) \[[@pone.0135683.ref043],[@pone.0135683.ref045],[@pone.0135683.ref049],[@pone.0135683.ref053],[@pone.0135683.ref056],[@pone.0135683.ref076],[@pone.0135683.ref077]\] and -12238T/C (n = 1)\[[@pone.0135683.ref078]\] were tested for the association of CHD. Thus, we only included rs662799 in the current meta-analysis. Among the published GWAS related to the current meta-analysis, we didn't find any direct information that could be applied in the current meta-analysis \[[@pone.0135683.ref012],[@pone.0135683.ref067],[@pone.0135683.ref079]\]. We further and added the WTCCC data to the meta-analysis. Please see the following figure for the updates ([Fig 2](#pone.0135683.g002){ref-type="fig"}). The current meta-analysis includes 40 studies comprised of 21378 cases and 28428 controls from 10 ethnic populations. Our meta-analysis contains at least 26 case studies and 3 ethnic populations more than were included in the last five meta-analyses published \[[@pone.0135683.ref023], [@pone.0135683.ref080]--[@pone.0135683.ref083]\]. All of the meta-analyses indicate that the *APOA5* rs662799 polymorphisms associated with CHD in the Chinese population, although many of the studies did not include a subgroup analysis stratified by ethnicity.

Despite the merits of our meta-analysis, there are limitations that must be considered. Our meta-analysis only includes studies from Asian and Caucasian populations. Therefore, it might not be an accurate representation of other ethnicities, such as African populations. Publication and language bias might exist in the case control studies \[[@pone.0135683.ref084]\]. The current meta-analysis was involved with 10 Caucasian and 30 Asian studies. Among the Asian studies, there were 24 Chinese studies (7 in English and 17 in Chinese). A further check for the minor allele frequency report in the HapMap International Project, we found the MAF in Europeans was 1.7% which was much less than 26.7% in Chinese and 29.1% in Japanese. However, subgroup meta-analyses by ethnicity found significant association of *APOA5* rs662799 and CHD in both Europeans and Asians. There may also be a selection bias in our meta-analysis, which only included studies published in English or Chinese. Finally, standards for diagnosis may vary due to differences in the inclusion of CHD cases and non-CHD controls.

In summary, our case-control and meta-analysis demonstrates that the frequency of the *APOA5* rs662799-G allele is significantly increased in CHD cases compared with controls. Furthermore, *APOA5* rs662799 interacts with both gender and age in the association with CHD.
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